Literature DB >> 8025739

Compartmentalized immune response reflects clinical severity of beryllium disease.

L S Newman1, C Bobka, B Schumacher, E Daniloff, B Zhen, M M Mroz, T E King.   

Abstract

Although beryllium disease has been associated with a bronchoalveolar lavage (BAL) lymphocytosis and T cell-mediated immune response, we do not know if either the BAL cellular profile or the compartmentalized pulmonary response to the antigen reflect the severity of the disease. We studied 110 subjects divided into three groups of subjects: beryllium disease patients (n = 55), beryllium-sensitized patients without disease (n = 8), and control subjects (n = 47). Evaluation included completion of a respiratory symptom questionnaire, clinical examination, chest radiograph, spirometry, body plethysmographic lung volumes, and diffusing capacity (DLCO). In the patient groups, we performed maximal exercise testing with an indwelling arterial line. In addition, we examined BAL and performed blood and BAL beryllium lymphocyte transformation tests (BeLT) as measures of the beryllium-specific T cell-mediated response in these two compartments. In beryllium disease patients we correlated the BAL cellular constituents with clinical parameters indicative of disease severity. Beryllium disease patients exhibited elevated numbers of white cells and lymphocytes in BAL compared with both other groups; however, this lymphocytic alveolitis was significantly obscured in smokers. The BAL cellular constituents correlated with BAL BeLT but not with the blood BeLT. BAL cellular constituents also correlated with the radiographic profusion of small opacities, FEV1/FVC, DLCO, maximal achievable work load, VO2max, and measures of gas exchange at rest and at maximum exercise. We conclude that the lymphocyte-predominant pulmonary inflammatory response in beryllium disease is related to the magnitude of the localized response to antigen and that BAL cellularity, differential cell count, and BeLT reflect beryllium disease clinical severity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025739     DOI: 10.1164/ajrccm.150.1.8025739

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

Review 1.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

Review 3.  Immunophenotyping of bronchoalveolar lavage lymphocytes.

Authors:  R J Harbeck
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.

Authors:  A P Fontenot; M Torres; W H Marshall; L S Newman; B L Kotzin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease.

Authors:  Andrew P Fontenot; Scott J Canavera; Laia Gharavi; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

6.  Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders.

Authors:  Y Inoue; T E King; S S Tinkle; K Dockstader; L S Newman
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

7.  DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease.

Authors:  Ivana V Yang; Iain Konigsberg; Kristyn MacPhail; Li Li; Elizabeth J Davidson; Peggy M Mroz; Nabeel Hamzeh; May Gillespie; Lori J Silveira; Tasha E Fingerlin; Lisa A Maier
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

8.  Current treatment of chronic beryllium disease.

Authors:  Akshay Sood
Journal:  J Occup Environ Hyg       Date:  2009-12       Impact factor: 2.155

Review 9.  The natural history of beryllium sensitization and chronic beryllium disease.

Authors:  L S Newman; J Lloyd; E Daniloff
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

Review 10.  Chronic beryllium disease: diagnosis and management.

Authors:  M D Rossman
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.